In the United States, there is discourse surrounding a novel bioengineering endeavor that its originators envision could eventually serve as a partial substitute for laboratory animals in scientific investigations.
This pertains to a creation by the startup R3 Bio, which proposes fabricating intricate biological constructs utilizing human cells, deliberately omitting the development of a brain structure.
According to Wired, the company posits that such systems could be employed to assess pharmaceuticals and the toxicity levels of various agents, obviating the need for animal subjects.
Looking ahead, those behind this concept also allude to the potential for cultivating bodily tissues and organs for medical applications. This initiative has garnered backing from investors who perceive both scientific breakthroughs and significant commercial viability, particularly within the realms of transplantation and longevity treatments.
Nevertheless, the technology remains in its nascent stages. Information from Wired suggests this is currently more of a foundational hypothesis and set of objectives rather than a finalized product.
About the Author
